PD-L1 stimulation enhanced osteoclast function and activity in PJI, as evidenced by increased expression of osteoclast-related markers, extracellular TRAP activity, and bone resorption, while nivolumab effectively mitigates these effects without compromising phagocytic activity. The gene discussed is ACP5; the disease is juvenile polyposis syndrome.